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BY-NC-ND license (http://creativecomBackground/purpose: Atrial flutter/fibrillation (AFL/Af) is a common late complication in
atrial septal defect (ASD) patients even after occluder implantation. We try to delineate the
risk factors of persistent AFL/Af.
Methods: From 1998 to 2010, all patients older than 18 years of age who received ASD occluder
implantation in our hospital were enrolled, and their records were retrospectively reviewed. In
addition, renineangiotensin system gene polymorphisms including angiotensinogen gene,
A1166C polymorphism on the angiotensin II type I receptor gene, and insertion/deletion (I/D)
patterns on the angiotensin-converting enzyme gene were checked using direct sequencing.
Results: A total of 517 patients (male/female 127/390) were enrolled. The mean age of pa-
tients receiving occluder deployment was 41.5  14.5 years. Prior to occluder deployment,
3.9% of patients had persistent Af, 3.1% of patients had paroxysmal Af, and 0.8% had AFL. After
a follow-up of 1894 patient-years, 3.5% had persistent Af and 1.9% of patients had paroxysmal
Af. The greatest risk factors of AFL/Af genesis included age, occluder size, presence of multiple
ASDs, and underlying thyroid or mitral valve disorder (p < 0.001, p < 0.001, p Z 0.033,
pZ 0.016, and pZ 0.012, respectively). Preoperative AFL/Af status is the most important fac-
tor in determining AFL/Af resolution and progression after an intervention. The renin
eangiotensin system gene polymorphisms had no association with AFL/Af genesis, and progres-
sion or resolution after intervention.ave no conflicts of interest relevant to this article.
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defect, Journal of the Formosan MedConclusion: AFL/Af is common after ASD occluder implantation, and predisposed by older age,
larger and multiple ASDs, and underlying disorders. Preoperative atrial arrhythmia status is the
most important predictor of AFL/Af progression or resolution. Renineangiotensin system gene
polymorphisms had no association with AFL/Af.
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Atrial septal defect (ASD) is one of the most common
congenital heart diseases in the adult population.1 Preva-
lence was as high as 3.2/1000 live births in our previous
population-based study.2 Without treatment, the mortality
and morbidity rate of hemodynamically significant ASD in-
creases significantly after 25 years of age.3 ASD occluder
implantation is now the mainstay of treatment for hemo-
dynamically significant ASD patients.4 We reported no
procedure mortality and low morbidity in the ASD patients
undergoing ASD occluder implantation in 2008.5 One of the
most common late complications of ASD is atrial flutter/
fibrillation (AFL/Af), which may be related to atrial dila-
tation after a long-term left to right shunt at the atrial
level.6 Without intervention, the prevalence of atrial
arrhythmia increases significantly with age, with reported
prevalence up to 13% after the age of 40 years, which is
significantly higher than that in general population.7
Although several reports have shown improvement of
AFL/Af after ASD repair, either through surgical repair or
after ASD occluder implantation, AFL/Af still complicates
certain patients with an incidence of 10e25% at the short-
term follow-up.8,9
AFL/Af is a common arrhythmia in elderly people.
Several recent studies have shown a genetic predisposition,
especially in the renineangiotensin system (RAS) gene in Af
patients.10,11 Angiotensin II activation can trigger the pro-
liferation of fibroblasts and cause myocardial fibrosis.11,12
Moreover, RAS gene haplotypes have a strong association
with Af.10 Whether this association exists in these ASD pa-
tients remains unknown. Using a large ASD cohort, we
attempted to define Af incidence and risk factors in ASD
patients receiving occluder deployment. We also tried to
identify the role of RAS gene polymorphisms in AFL/Af
genesis.Materials and methods
From 1998 to 2010, all adult patients (>18 years of age) who
received ASD occluder implantation in National Taiwan
University Hospital were retrospectively included in our
study. The occluders we used were Amplatzer septal
occluders (AGA Medical Corporation, Plymouth, MN, USA).
The study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki, as reflected in an a priori
approval by the Human Research Committee in National
Taiwan University Hospital. The basic clinical characteris-
tics, hemodynamic and cardiac catheterization reports, andhiu S-N, et al., Atrial flutter/fibr
ical Association (2016), http://dfollow-up data were collected through a chart review. We
evaluated the pre- and postoperative clinical symptoms,
electrocardiography (EKG) data, and 24-hour Holter study
results. Persistent Af is defined as Af that persists for longer
than 7 days (at all available EKG and Holter reports).
Paroxysmal Af is defined as self-terminating Af if it ceased
spontaneously during the 24-hour Holter examination, or if it
did not persist in the whole surface EKG. The cardiac cath-
eterization data, including pulmonary blood flow/systemic
blood flow (Qp/Qs), pulmonary artery pressure, and
occluder size, were also recorded. For patients with multiple
ASDs, either multiple occluders were implanted or one
occluder was deployed for the larger hole. For patients with
significant pulmonary hypertension, fenestrated occluders
were deployed for safety. We considered postoperative AFL/
Af positive when the AFL/Af occurred after discharge. The
arrhythmias developing during or immediately after the
procedure, but self-terminating thereafter were regarded as
negative, as these might relate to the procedure only. Mitral
valve disease in our study is defined as more than moderate
degree mitral regurgitation or mitral stenosis during echo-
cardiography examination, no matter what the etiology is.
The RAS gene polymorphisms were analyzed after
receiving informed consent. Five milliliters of fresh blood
were withdrawn and stored in an EDTA tube. Genomic DNA
was then extracted. Previously identified I/D polymorphisms
on the angiotensin-converting enzyme (ACE) gene; T174M,
M235T, G-6A, A-20C, G-152A, and G-217A polymorphisms on
the angiotensinogen gene; and A1166C polymorphism on the
angiotensin II type I receptor gene were checked using
direct sequencing. Previously used primer pairs were used
to amplify these exons.10 A polymerase chain reaction was
conducted using 50 ng template DNA, 2.5 pmol primers,
1 mL Mg2þ (25mM), and 1 mL Master Mix containing deoxy-
ribonucleotide triphosphate (dNTP) and Taq polymerase.
Dye terminator sequencing using an ABI 3730 automatic
sequencer (Applied Biosystems, Foster City, CA, USA) was
then performed. The results were analyzed using the Gen-
otyper program (Life Technologies, San Francisco, CA, USA).
The results of the RAS gene haplotypes were compared
between those with and without AFL/Af.
Statistical analysis
The data were presented as mean (standard deviation).
Student t test was used for a numerical data comparison.
The chi-square test and Fisher’s exact test were used for a
categorical data comparison. Logistic regression was used
for multivariate risk factor analysis. Statistical significance
was defined as p < 0.05.illation in patients receiving transcatheter closure of atrial septal
x.doi.org/10.1016/j.jfma.2016.09.005
Figure 1 AFL/Af before and after occluder deployment in
517 ASD patients. a Three of four patients of AFL had also
paroxysmal Af at preoperative Holter examination. AfZ atrial
fibrillation; AFL Z atrial flutter; ASD Z atrial septal defect.
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In total, 517 ASD patients were enrolled in our study. Male/
female ratio was 127/390. The basic clinical characteristics
are shown in Table 1, and the AFL/Af status is shown in
Figure 1. Prior to occluder deployment, 3.9% of the patients
had persistent Af, 3.1% had paroxysmal Af, and 0.8% had
AFL (3 of the 4 patients had concomitant paroxysmal Af at
Holter examination). The mean interval between the
diagnosis of AFL/Af and device placement was
1.5  2.9 years. After a follow-up of 1894 patient-years,
3.5% of the patients had persistent Af and 1.9% had
paroxysmal Af after ASD occluder deployment. Two of the
20 patients with persistent Af preoperatively had Af reso-
lution (1 received radiofrequency catheter ablation before
occlude deployment and another received cardioversion
during occluder implantation) after 5e64 months of follow-
up. For the four patients with AFL before occluder im-
plantation, the AFL improved in all of them (2 received
radiofrequency ablation and the other 2 received cardio-
version during occluder implantation). For the other 477
patients without preoperative AFL/Af, one progressed to
persistent Af after 4.5 years of follow-up. Another five
patients had paroxysmal Af during follow-up. Most of the
patients with Af received antiarrhythmia medication
including beta-blockers, and class Ic or III antiarrhythmia
medication both before and after ASD closure.
The AFL/Af risk factor analysis is shown in Table 1. We
identified that an underlying disease (including metabolic
syndrome, thyroid dysfunction, and mitral valve disorder),
age of cardiac catheterization, mean pulmonary artery
pressure, size of the occluders used, multiple ASDs, and
fenestrated occluder use all were significant risk factors of
AFL/Af either before or after ASD occluder deploymentTable 1 Basic clinical characteristics and risk factor analysis
patients.
Variables All patients With AFL/Af Without
AFL/Af
(n Z 517) (n Z 46) (n Z 47
Age of catheterization 41.5  14.5 61  11.4 39.6  1
Sex, female (%) 75.4 67.4 76.2
Underlying disease
Metabolic syndrome 18.2% 45.7% 15.5%
Coronary artery disease 2.9% 13% 1.9%
Hypertension 12.2% 23.9% 11%
Thyroid dysfunction 3.7% 13.0% 2.8%
Mitral valve disease 0.96% 8.7% 0.2%
Body weight 57.8  11.5 59  13.1 57.7  1
Qp/Qs 2.9  1.1 2.9  1.0 2.9  1.
Mean pulmonary
artery pressure
19.8  8.4 26.3  9.2 19.1  8
Size of occluder 26  7 30.2  7.3 25.1  7
Multiple ASD 4.8% 10.9% 4.2%
Fenestrated
occluder needed
2.5% 15.2% 1.3%
AFL/Af Z atrial flutter/fibrillation; ASD Z atrial septal defect.
a The multivariate regression analysis consists of the significant var
Please cite this article in press as: Chiu S-N, et al., Atrial flutter/fibri
defect, Journal of the Formosan Medical Association (2016), http://dduring the follow-up. We then enrolled the significant var-
iables analyzed in univariate regression analysis and per-
formed multivariate regression analysis (Table 1). We found
that the age of cardiac catheterization, size of the
occluders used (corresponding to ASD size), presence of
multiple ASDs, and underlying thyroid and mitral valve
disorders resulted in a significantly higher risk after
adjusting for other variables.of atrial flutter/fibrillation in our 517 atrial septal defect
Univariate regression Multivariate regressiona
1) Odds ratio p Odds ratio p
3.3 1.117 <0.001 1.134 (1.096e1.173) <0.001
0.645 0.187
4.58 <0.001
7.69 <0.001
2.53 0.013
6.87 <0.001 5.807 (1.392e24.23) 0.016
44.7 0.001 88.64 (2.727e2880) 0.012
1.4 1.010 0.448
1 1.004 0.976
.0 1.071 <0.001
.1 1.108 <0.001 1.174 (1.1e1.252) <0.001
2.750 0.037 5.488 (1.151e26.16) 0.033
13.91 <0.001
iables in univariate regression analysis (p < 0.05).
llation in patients receiving transcatheter closure of atrial septal
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AFL/Af and attempted to define factors that would cause
AFL/Af resolution after ASD occluder implantation. We
found that only preoperative AFL/Af status had a significant
negative correlation with later AFL/Af improvement
(persistent Af vs. AFL or paroxysmal Af, odds ratio 33.8, 95%
confidence interval 5.4e210.5, p < 0.001). Excluding pre-
operative AFL/Af status (i.e., persistent Af vs. AFL or
paroxysmal Af), we could not find other factors significantly
related to AFL/Af improvement.
We also analyzed the other 477 patients without pre-
operative AFL/Af and attempted to identify risk factors of
AFL/Af progression after occluder implantation. Using a
multivariate logistic regression model, we found that the
presence of short-run atrial tachycardia during the Holter
examination and underlying mitral valve disease were
associated with the highest risk of AFL/Af progression with
odds ratios of 13.9 (95% confidence interval 1.6e111.1,
p Z 0.016) and 236.1 (95% confidence interval 10.5e5320,
p Z 0.001), respectively. In addition, multiple occluder
implantation and fenestrated occluder use also increased
the risk of later AFL/Af progression with odds ratios of 12.4
and 10.9 (p Z 0.045 and 0.084), respectively.
The distribution of RAS gene polymorphisms in 263 ASD
patients is shown in Table 2. The distribution showed no
significant difference between those with and without AFL/
Af (Table 2). The RAS haplotypes in these 263 patients are
shown in Table 3. We did not find a significant associationTable 2 Renineangiotensin system gene polymorphisms in a
fibrillation.
Locus Genotype alleles All ASD patients (n Z 263
ACE gene I/D II 124 (47.5)
ID 107 (41.0)
DD 30 (11.5)
AT1R gene A1166C AA 246 (93.5)
AC 17 (6.5)
CC 0
AGT gene G-217A GG 181 (68.8)
GA 66 (25.1)
AA 16 (6.1)
G-152A GG 247 (93.9)
GA 15 (5.7)
AA 1 (0.4)
A-20C AA 202 (76.8)
AC 56 (21.3)
CC 5 (1.9)
G-6A GG 10 (3.8)
GA 77 (29.3)
AA 176 (66.9)
T174M TT 221 (84)
TM 40 (15.2)
MM 2 (0.8)
M235T MM 7 (2.7)
MT 80 (30.4)
TT 176 (66.9)
Data are presented as n (%).
ACE Z angiotensin-converting enzyme; AFL/Af Z atrial flutter/fib
AT1R Z angiotensin II type I receptor.
Please cite this article in press as: Chiu S-N, et al., Atrial flutter/fibr
defect, Journal of the Formosan Medical Association (2016), http://dbetween the 16 different haplotypes found in our patients
and AFL/Af. We used two- and three-way gene interaction
analysis, but we found no significant association between
RAS gene polymorphisms and AFL/Af in the ASD patients.
We also analyzed those with Af and excluded four AFL pa-
tients. There was no association between RAS gene poly-
morphisms and Af in the ASD patients. We also found that
RAS gene polymorphisms had no significant association with
AFL/Af resolution in 40 patients with preoperative AFL/Af.
In addition, it also showed no significant association with
AFL/Af progression in 477 patients without preoperative
AFL/Af.Discussion
Using this large-scale ASD cohort, we found the following:
(1) Older age at the time of intervention, a larger ASD,
multiple ASDs, and underlying thyroid and mitral
valve disorder can be used to predict AFL/Af genesis.
(2) Paroxysmal Af and AFL often resolve after ASD
closure, but persistent Af seldom resolves. Preoper-
ative atrial arrhythmia status is the strongest risk
factor of later AFL/Af progression or resolution.
(3) RAS gene polymorphisms showed no association
either with AFL/Af genesis or with the progression or
resolution of AFL/Af after ASD intervention.trial septal defect patients with or without atrial flutter/
) With AFL/Af (n Z 38) Without AFL/Af (n Z 225) p
22 (57.9) 102 (45.7) 0.366
12 (31.6) 95 (42.6)
4 (10.5) 26 (11.7)
36 (94.7) 210 (93.3) >0.99
2 (5.3) 15 (6.7)
25 (65.8) 156 (69.3) 0.433
12 (31.6) 54 (24)
1 (2.6) 15 (6.7)
37 (97.4) 210 (93.3) 0.619
1 (2.6) 14 (6.2)
0 1 (0.4)
30 (78.9) 172 (76.4) 0.647
8 (21.1) 48 (21.3)
0 5 (2.2)
2 (5.3) 8 (3.6) 0.454
8 (21.1) 69 (30.7)
28 (73.7) 148 (65.8)
31 (81.6) 190 (84.4) 0.715
7 (18.4) 33 (14.7)
0 2 (0.9)
1 (2.7) 6 (2.7) 0.836
10 (26.3) 70 (31.1)
27 (71.1) 149 (66.2)
rillation; AGT Z angiotensinogen; ASD Z atrial septal defect;
illation in patients receiving transcatheter closure of atrial septal
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Table 3 Frequency of haplotypes in angiotensinogen gene in our atrial septal defect patients.
Haplotype 217 152 20 6 3889 4072 Frequency p
H1 G G A A C C 0.263 0.687
H2 A G A A C C 0.237 0.404
H3 G G A G C T 0.210 0.520
H4 G G A A T C 0.004 >0.99
H5 G G C A T C 0.095 0.764
H6 G A A A C C 0
H7 G G A G C C 0.008 >0.99
H8 G G A A C T 0.004 >0.99
H9 G A C A C C 0.023 >0.99
H10 A G A A T C 0
H11 G G A G T T 0
H12 G G C A C C 0.008 >0.99
H13 G G C G C T 0.008 >0.99
H14 G G C G T T 0.038 0.154
H15 G A C G C T 0.027 0.598
H16 A G A G C T 0.046 >0.99
H17 A G C A C C 0.004 >0.99
H18 A G C A T C 0.019 >0.99
H19 A A C A C C 0.008 >0.99
The p value of frequency comparing those with and without Af is also shown in the table.
Af Z atrial fibrillation.
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ASD. In the past, open heart surgery was required to correct
this congenital heart disease for long-term survival.3
Currently, most ASDs smaller than 40 mm with adequate
rims are corrected through transcatheter ASD occluder
deployment, yielding favorable results.13 Although no ran-
domized clinical trial compares the result of surgical
closure and transcatheter closure of ASD, several reports
have shown comparable mortality and complication rates
between the two groups. Minor morbidity, length of hos-
pital stay and intensive care unit stay, and emotional anx-
iety are significantly lower in transcatheter approach
patients.13e15 Therefore, transcatheter closure is now the
mainstay of ASD treatment: in our hospital, most ASD pa-
tients received transcatheter closure rather than an
operation.4,5
In the general population, the incidence of Af is <0.1% in
those younger than 40 years of age and increases gradually
with age. The prevalence rate is 1.4% in men and 0.7% in
women in our study population older than 40 years of age.16
In our study, 8.9% of ASD patients have AFL/Af either before
or after occluder implantation. The reason for the high
incidence of AFL/Af in ASD patients remains unclear. Using
multivariate regression analysis, we found that the age of
transcatheter closure, size of the device (which corre-
sponded to the size of ASD), presence of multiple ASD, and
underlying disorders (thyroid or mitral valve disorder) were
the most important AFL/Af genesis risk factors. These re-
sults corresponded with those of previous studies.8,9,17
Older age and large or multiple ASDs all resulted in high
right atrial wall stress, which then caused right atrial wall
thickening and fibrosis. This may be the AFL/Af substrate in
ASD patients. This result implied that earlier closure of ASD,
especially for those with large and multiple ASDs, is
mandatory to prevent the development of Af.Please cite this article in press as: Chiu S-N, et al., Atrial flutter/fibri
defect, Journal of the Formosan Medical Association (2016), http://dAlthough several reports have shown an improvement in
AFL/Af after ASD repair through surgical repair or ASD
occluder implantation, AFL/Af may still pose complications
in certain patients. Among them, 8e11.6% experienced a
new onset of AFL/Af.17 In our study, of those with preop-
erative persistent Af, only 20% had Af improvement. How-
ever, of those with preoperative paroxysmal Af, 81.3% had
Af improvement, and of those with preoperative AFL, all
had AFL resolution. Regression analysis shows that preop-
erative AFL/Af status was the only significant predictor of
AFL/Af resolution. This corresponds with previous reports
that persistent AFL/Af seldom improved after ASD closure.
However, three of the four patients who received trans-
catheter ablation for Af either before or after ASD occluder
implantation had Af resolution during short-term follow-up.
Further studies are needed to investigate whether preop-
erative transcatheter ablation can eliminate Af.
For those without preoperative AFL/Af, 1.3% still pro-
gressed to either paroxysmal or persistent Af after an
average 4.5-year follow-up. Multivariate regression analysis
revealed that the greatest predictors of later progression
were preoperative atrial arrhythmia and underlying mitral
valve disorder, followed by multiple occluder implantation
and fenestrated occluder use. The result suggests that
preoperative atrial arrhythmia is a warning sign of later Af
progression, and close follow-up is necessary for these pa-
tients. For patients with underlying mitral valve disorder, it
is reasonable that Af may progress even after ASD closure
because mitral valve disorder is an important risk of Af
genesis even in non-ASD patients.18 In addition, we found
that multiple occluder implantation (which often corre-
sponded to a larger ASD and shunt) and more than moder-
ate degree pulmonary hypertension (which corresponded to
fenestrated occluder use) are also predictors of later AFL/
Af progression. Therefore, in these patients, close follow-llation in patients receiving transcatheter closure of atrial septal
x.doi.org/10.1016/j.jfma.2016.09.005
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intervention.
Af is a common sustained arrhythmia in elderly people.
The mechanism is thought to be related to atrial structural
remodeling because of atrial dilatation, fibrosis, and elec-
trical remodeling resulting from the shortening of the atrial
refractory period.19 The interaction between genetic and
environmental factors was previously believed to
contribute to the risk of Af development. In previous
studies, several candidate genes such as connexin 40,
SCN5A, potassium channel genes, and the RAS genes
showed a strong association with Af patients.10,11 Among
the studied genes, the RAS genes received the most
attention. In the animal model with cardiac-restricted ACE
expression, mice conveyed severe atrial dilatation and Af.
Several other studies have also shown that angiotensin II
can trigger a mitogen-activated protein kinase pathway,
causing proliferation of the fibroblasts, cardiomyocyte
fibrosis, and hypertrophy.12,20 In addition, two large-scale
caseecontrol studies conducted at our hospital revealed
that the specific haplotypes at six loci (T174M, M235T, G-
6A, A-20C, G-152A, and G-217A) of angiotensinogen, com-
bined with haplotypes at ACE and angiotensin II type I re-
ceptor gene, had a strong association with Af patients. This
implied that RAS gene polymorphisms may predispose the
genesis of lone Af when accompanied by environmental
factors.10 However, in our current study, RAS gene poly-
morphisms did not show any association with the genesis,
progression, or resolution of Af in ASD patients. Therefore,
Af development in these ASD patients may be relatively
different from that in patients with lone Af.21 This result
implies that the RAS blocker, as an ACE inhibitor, may have
no effect on the prevention of Af in these ASD patients.
In patients with lone Af, the pulmonary vein is consid-
ered the most important focus for arrhythmia. In ASD pa-
tients, because right atrial dilatation is the pathognomonic
feature, the Af foci should be different from those with
lone Af, and were previously considered at the right atrium.
Several reports have been proposed on the resolution of
chronic Af after right atrial separation in ASD patients.22
However, a recent report suggested that the right atrial
maze had a lower long-term arrhythmia-free survival rate
compared with the biatrial maze.23 Therefore, they sug-
gested that the anatomical and molecular mechanisms of
ASD patients were complex, and the right atrial dilatation
and pulmonary vein foci may all play some roles. In our
study, we found that the mitral valve disorder was an
important risk factor of later atrial arrhythmia progression.
This suggested that not all cases of Af in ASD patients are
related to right atrial dilatation. Some of the Af in ASD
patients may relate to left atrial dilatation secondary to
mitral valve disorder. In addition, of the four patients who
received pulmonary vein foci ablation for Af, the Af
resolved in three patients at short-term follow-up. This also
supported that the pulmonary vein foci may also be
important in these ASD patients. Further study is warranted
to determine if the pulmonary vein isolation before ASD
occluder deployment can cause later Af regression.
As a retrospective study, not all our patients had 24-hour
Holter EKG data (only 11/20 patients had preoperative 24-
hour Holter study) before occluder implantation, but all our
patients with Af underwent postoperative 24-hour HolterPlease cite this article in press as: Chiu S-N, et al., Atrial flutter/fibr
defect, Journal of the Formosan Medical Association (2016), http://dexamination. For those without preoperative 24-hour Hol-
ter data, we could only define the preoperative Af status
according to all available EKG data at clinics, and EKG
monitoring data during admission and cardiac catheteriza-
tion. This may decrease the study power of our study.
In conclusion, AFL/Af is a common late complication in
hemodynamically significant ASD patients, and it occurred
in 8.9% of the patients in our long-term follow-up. Older
age at the time of ASD closure, a larger ASD, existence of
multiple ASDs, and underlying thyroid or mitral valve dis-
order are significant indicators of AFL/Af occurrence. Pre-
implantation atrial arrhythmia predicted later Af
progression and resolution. RAS gene polymorphisms were
not associated with AFL/Af in ASD patients.
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